What's Happening?
GC Biopharma has published a study on the lysosomal delivery mechanism of Hunterase, a therapy for Hunter syndrome, in the International Journal of Biological Macromolecules. The study reveals the role of N-glycosylation in targeting the enzyme to lysosomes, crucial for treating the genetic disorder. The research identified 42 N-glycan structures, with key sites modified for efficient delivery. The findings demonstrate high-affinity binding to receptors and prolonged circulation due to sialic acid modifications.
AD
Why It's Important?
The study advances understanding of enzyme replacement therapies for rare genetic disorders, potentially improving treatment efficacy. It highlights the importance of targeted drug delivery in biotechnology, influencing future research and development in the field. The publication in a prestigious journal underscores the significance of the findings in the scientific community.
